Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii
Antimicrobial Agents and Chemotherapy · 04.06.2025 · 69 (6)
DOI: 10.1128/aac.01880-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.06.2025. Verfasst von Jaehoon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hallym University College of Medicine, Chuncheon, Gangwon, South Korea. Hauptthemen laut MEDLINE: Colistin, Ampicillin, Acinetobacter baumannii, Sulbactam. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hallym University, Korea National Institute of Health.
Abstract (Originalsprache)
Differences exist between Infectious Diseases Society of America guidance and European Society of Clinical Microbiology and Infectious Diseases guidelines on treating pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB). This study compared the outcomes of colistin-based and high-dose ampicillin/sulbactam-based combination therapies in patients with CRAB nosocomial pneumonia. A retrospective cohort study was conducted at a university-affiliated hospital in South Korea. Patients received either a colistin-based regimen with a loading dose followed by a maintenance dose (June 2021–May 2022) or a high-dose ampicillin/sulbactam-based regimen with sulbactam 9 g/day (October 2022–September 2023). The primary outcome was 28-day all-cause mortality; secondary outcomes included 14-day/28-day clinical success rates and 14-day/28-day kidney injury based on the Risk, Injury, Failure, Loss, End-stage renal disease score. Logistic and Poisson regression analyses were used to compare outcomes between groups. Among 179 patients enrolled in the study, 84 received the colistin-based regimen and 95 received the high-dose ampicillin/sulbactam-based regimen. The ampicillin/sulbactam group showed significantly lower 28-day mortality (20% vs. 61%; adjusted relative risk [aRR] = 0.16, 95% CI 0.08–0.32). Clinical success rates were higher in the ampicillin/sulbactam group at both 14 days (39% vs. 23%; aRR = 2.19, 95% CI 1.10–4.37) and 28 days (55% vs. 32%; aRR = 2.71, 95% CI 1.14–5.20). Additionally, 28-day kidney injury was lower in the ampicillin/sulbactam group (0.63 ± 1.16 vs. 1.06 ± 1.35; aRR = 0.56, 95% CI 0.40–0.79). High-dose ampicillin/sulbactam-based combination therapy demonstrates superior outcomes over colistin-based combination therapy for CRAB nosocomial pneumonia, including lower mortality, higher clinical success rates, and reduced kidney injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hallym University College of Medicine, Chuncheon, Gangwon, South Korea.
- Department of Life Science, Multidisciplinary Genome Institute, Hallym University, Chuncheon, Gangwon, South Korea.
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Gangwon, South Korea.
- Division of Infectious Diseases, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Gangwon, South Korea.
ORCID-Profile: Jaehoon Lee, Imchang Lee, Ki-Byung Lee, Seung Soon Lee
Förderung
- Hallym University
- Korea National Institute of Health
Zitieren
APA
Lee, J., Lee, I., Lee, K. B., & Lee, S. S. (2025). Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 69(6). https://doi.org/10.1128/aac.01880-24
Vancouver
Lee J, Lee I, Lee KB, Lee SS. Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2025;69(6). doi:10.1128/aac.01880-24
BibTeX
@article{Lee2025,
author = {Lee, Jaehoon and Lee, Imchang and Lee, Ki-Byung and Lee, Seung Soon},
title = {Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {6},
doi = {10.1128/aac.01880-24}
}
EUVIMED